Literature DB >> 12667653

The EAE-associated behavioral syndrome: II. Modulation by anti-inflammatory treatments.

Y Pollak1, H Ovadia, E Orion, R Yirmiya.   

Abstract

EAE is associated with sickness behavior symptoms that are temporally correlated with inflammatory processes. To further elucidate the role of inflammatory mediators in the behavioral syndrome, EAE mice were injected daily with anti-inflammatory drugs, beginning at disease onset. Dexamethasone or interleukin-1 (IL-1) receptor antagonist or the prostaglandins synthesis inhibitor indomethacin attenuated the behavioral symptoms. Administration of the tumor necrosis-factor alpha (TNF-alpha) synthesis inhibitor pentoxifylline or targeted deletion of the type I TNF receptor had no behavioral effects whereas administration of pentoxifylline in IL-1ra-treated mice further reversed the behavioral depression. These findings demonstrate the critical involvement of pro-inflammatory cytokines and prostaglandins in the EAE-associated behavioral syndrome, and may have implications for understanding and treating the neuropsychiatric disturbances in multiple sclerosis (MS) patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667653     DOI: 10.1016/s0165-5728(03)00073-0

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  15 in total

1.  Psychopathology in multiple sclerosis: diagnosis, prevalence and treatment.

Authors:  Ida S Haussleiter; Martin Brüne; Georg Juckel
Journal:  Ther Adv Neurol Disord       Date:  2009-01       Impact factor: 6.570

2.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

3.  Biological outcome measurements for behavioral interventions in multiple sclerosis.

Authors:  Anja Fischer; Christoph Heesen; Stefan M Gold
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

Review 4.  The link between multiple sclerosis and depression.

Authors:  Anthony Feinstein; Sandra Magalhaes; Jean-Francois Richard; Blair Audet; Craig Moore
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

Review 5.  Depressive syndromes in neurological disorders.

Authors:  Julian Hellmann-Regen; Dominique Piber; Kim Hinkelmann; Stefan M Gold; Christoph Heesen; Carsten Spitzer; Matthias Endres; Christian Otte
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-11       Impact factor: 5.270

6.  Endogenous glucocorticoids protect against TNF-alpha-induced increases in anxiety-like behavior in virally infected mice.

Authors:  M N Silverman; M G Macdougall; F Hu; T W W Pace; C L Raison; A H Miller
Journal:  Mol Psychiatry       Date:  2006-11-21       Impact factor: 15.992

Review 7.  Depression and immunity: inflammation and depressive symptoms in multiple sclerosis.

Authors:  Stefan M Gold; Michael R Irwin
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

Review 8.  From inflammation to sickness and depression: when the immune system subjugates the brain.

Authors:  Robert Dantzer; Jason C O'Connor; Gregory G Freund; Rodney W Johnson; Keith W Kelley
Journal:  Nat Rev Neurosci       Date:  2008-01       Impact factor: 34.870

9.  Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.

Authors:  Georgia Mandolesi; Alessandra Musella; Antonietta Gentile; Giorgio Grasselli; Nabila Haji; Helena Sepman; Diego Fresegna; Silvia Bullitta; Francesca De Vito; Gabriele Musumeci; Claudio Di Sanza; Piergiorgio Strata; Diego Centonze
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

10.  Acute illness-induced behavioral alterations are similar to those observed during withdrawal from acute alcohol exposure.

Authors:  Laura Richey; Tamara L Doremus-Fitzwater; Hollin M Buck; Terrence Deak
Journal:  Pharmacol Biochem Behav       Date:  2012-08-17       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.